News

Novavax (NASDAQ:NVAX) executives used the company’s first-quarter 2026 earnings call to highlight continued progress in reshaping the business around partner-driven revenue, a leaner operating model, and selective internal R&D designed to seed additional collaborations. Strategy centered on par

Pfizer (NYSE:PFE) chief executive Albert Bourla has signaled a possible shift in tone around US vaccine policy, praising President Donald Trump's latest nominee to lead the Centers for Disease Control and Prevention after a turbulent year for the agency. In a Bloomberg TV interview Tuesday, Bourla called Erica Schwartz a very credible scientist, pointing to what could be a more conventional choice for the country's top public health role. Schwartz, who holds both medical and law degrees and previously served as deputy surgeon general during the first Trump administration, is now being viewed as a figure who could help stabilize an agency that has become increasingly important for vaccine makers.

U.S. stocks ended higher on Tuesday, with the S&P 500 and the Nasdaq hitting new all-time highs, as oil prices slid and robust earnings from AI-related stocks lifted investors' sentiment.

The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.

Operational revenue from Pfizer’s Covid vaccine Comirnaty and Paxlovid pill to treat the illness declined 59% and 63%, respectively.

FDA approves VEPPANU (vepdegestrant), the first PROTAC protein degrader therapy, for ER+/HER2-, ESR1-mutated advanced breast cancer. Pfizer and Arvinas co developed VEPPANU, targeting patients who face significant challenges with endocrine resistance. Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma report positive outcomes, strengthening Pfizer's oncology pipeline. For investors following NYSE:PFE, these oncology milestones arrive with the stock trading around $26.3...

Moby summary of Pfizer Inc.'s Q1 2026 earnings call

Pfizer Chief Executive Albert Bourla is battling impending expirations for some blockbuster-drug patents and the precipitous decline of the company's Covid franchise, but he has put a date on when the company will return to consistent growth: 2029. Bourla said Tuesday he expects Pfizer will post high-single-digit average revenue growth annually from 2029 through 2033. “Products are losing patents, and we have a clear line of sight on growth starting in '29,” Bourla said in an interview after the company reported better-than-expected first-quarter results.

May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling ‌on its COVID-19 vaccine. The New York-based drugmaker also beat Wall Street expectations for first-quarter revenue and profit, buoyed by strong demand for its ‌blood thinner Eliquis and recently acquired products, as it faces looming patent expirations and fading COVID produ

Raising capital while still building the data needed to validate an idea is often one of the biggest hurdles for start-ups.

Markets Await New Home Sales Data

BioNTech (NASDAQ:BNTX) executives used the company’s first-quarter 2026 earnings call to highlight a strategy centered on combination oncology therapies, provide updates on late-stage clinical programs, and outline capital allocation plans that include a $1 billion ADS share repurchase program and m

Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The S&P 500 (^GSPC) heads into Tuesday with momentum after a powerful rebound last month in which the broader markets advanced 9%. A pullback in crude oil and first-quarter earnings beats are driving today’s gains as the markets embrace a reprieve in the Mideast escalation. The S&P 500 (^GSPC) is capturing those tailwinds for gains ... S&P 500 Rises on Big Tech Bump, Corporate Profits and Oil Price Relief

Pfizer stock edged higher early Tuesday on stronger-than-expected first-quarter sales and earnings. The company kept its outlook.

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q1 CY2026, with sales up 5.4% year on year to $14.45 billion. On the other hand, the company’s full-year revenue guidance of $61 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.75 per share was 3.9% above analysts’ consensus estimates.

Pfizer CEO Albert Bourla and Accenture CEO Julie Sweet discuss how they’re using AI to transform their work. Watch the full episode of The 1 on 1 with CNN at CNN.com/the1on1.

Pfizer (PFE) delivered earnings and revenue surprises of +5.63% and +4.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

The company said it would exit operations at some manufacturing plants in Germany and Singapore, and cut 1,860 positions in total.

US equity futures were trending higher on Tuesday as traders await a fresh batch of corporate earnin

Earnings season revs up the next few days as investors will hear from big companies including Advanced Micro Devices, CoreWeave, Pfizer and McDonald's. Data on the U.S. jobs market will also be watched closely, culminating in April nonfarm payroll numbers Friday.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors should know.

The markets got an unwelcome reminder today that the war in Iran isn’t over, clouding a picture that’s recently been dominated by sunny earnings reports. On Monday, the Dow Jones Industrial Average lost 557 points, or 1.1%, while the S&P 500 declined 0.4% and the Nasdaq Composite slipped 0.2%; the latter two had closed out last week at fresh highs. The war in the Middle East, which Wall Street had all but ignored in recent weeks, flared back into view on Monday.

Asking for a Trend Host Josh Lipton previews several of the biggest stories to come tomorrow, Tuesday, May 5, including earnings results from Advanced Micro Devices (AMD), Pfizer (PFE), and Anheuser-Busch Inbev (BUD); fresh labor data in the form of the latest Job Openings and Labor Turnover Survey (JOLTS) report; and commentary from Federal Reserve Vice Chair for Supervision Michelle Bowman and Governor Michael Barr.

Pfizer Inc. will release earnings for its third quarter before the opening bell on Tuesday, May 5. Analysts expect the pharmaceutical company to report quarterly earnings of 72 cents per share. That’s down from 92 cents per share in the year-ago period. Benzinga Pro puts the consensus estimate for Pfizer's quarterly revenue at $13.8 billion. Pfizer reported $13.71 billion last year. With the recent buzz around the company, some investors are eyeing potential gains from its dividends. Currently,

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs. Moderna leaned on cost cuts and international expansion to soften a steep COVID revenue cliff. Two very different pharma stories, both shaped by life ... Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era